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frameworks UiO66-NH2 and UiO66 –
encapsulation vs. conjugation
Katarzyna A. Mocniak,a Ilona Kubajewska,b Dominic E. M. Spillane,c
Gareth R. Williamsb and Russell E. Morris*a
This work demonstrates synthetic strategies for the incorporation of an anticancer drug, cisplatin, and a
Pt(IV) cisplatin prodrug into two zirconium-based metal–organic-frameworks (MOFs): UiO66 and UiO66-
NH2. Cisplatin was chosen due to its reported high potency in killing ca. 95% of diﬀerent cancers. Two
approaches for its incorporation were investigated: conjugation and encapsulation. In the conjugation
route, a Pt(IV) cisplatin prodrug was incorporated into UiO66-NH2 utilising its amine group in an amide-
coupling reaction. In the second case, cisplatin was encapsulated into the large cavities of both MOFs.
The presence of platinum was conﬁrmed by energy-dispersive X-ray spectroscopy and microwave
plasma-atomic emission spectroscopy. The cytotoxicity of the formulations was assessed on the A549
lung cancer cell line. The results show that the system in which cisplatin is conjugated to UiO66-NH2 is
more eﬃcient in inducing cell death than the materials where cisplatin is encapsulated into the pores of
the MOFs. This is consistent with the higher drug loading achieved with the conjugation technique. One
disadvantage of cisplatin therapy is that it may lead to thrombosis and, as a consequence, to heart attack
and cardiac arrest. To ameliorate this potential side eﬀect, we investigated the incorporation of NO
(which has been widely researched for its antithrombotic properties) into the drug-loaded MOFs. All the
cisplatin or pro-drug loaded MOFs are able to entrap and then release NO. Furthermore, the amount of
NO released from these formulations is much greater than from the pure MOFs. As a result, the drug
delivery systems developed in this work have potentially potent double functionality.Introduction
Cancer is one of the most feared diseases known to mankind.
Therefore, the development of new andmore eﬃcient drugs has
continuously attracted a great deal of attention. There are a
number of known anticancer drugs targeting diﬀerent meta-
bolic pathways, such as alkylating agents (busulfan, melphalan,
chlorambucil), anti-metabolites (asparaginase, 5-uorouracil,
methotrexate) or DNA linking agents (carboplatin, cisplatin or
oxoplatin). Cisplatin, cis-[Pt(NH3)2Cl2], is the most commonly
used and researched drug for a variety of cancers. Despite its
high toxicity (due to being a rst generation drug), cisplatin is
used in the treatment of head, neck, ovarian, cervical, testicle,
breast and bladder tumours.1 The toxicity of cisplatin against
cancerous cells was rst recognized in 1968.2 Over subsequent
years of intensive research, it showed high eﬃcacy against manyws, North Haugh, St Andrews, KY16 9ST,
4 (0)1334 463818
London, 29–39 Brunswick Square, WC1N
litan University, 166-220 Holloway Road,
56cancer types in clinical trials3 and was nally approved as an
anti-tumour drug by the FDA (Food and Drug Administration)
in 1978.4 Cisplatin is capable of forming intra- and inter-strand
cross-links with nucleic acids of DNA. This leads to cell death
(apoptosis) due to the resultant inability of DNA to replicate.5
It must be noted that cisplatin does not act very specically,
and aﬀects all cells as it cannot distinguish between cancerous
and healthy cells. Even though its clinical eﬀectiveness is rela-
tively high, it comes with many side-eﬀects including nephro-
toxicity and neurotoxicity, together with possible development
of drug resistance over time. Many trials have targeted the
synthesis of so-called “warheads” that can target the unique
metabolic pathways of tumour cells (such as the glucose-based
respiration that causes them to oﬀer a reductive environment6),
thereby increasing specicity. Non-toxic Pt(IV) species can be
activated into Pt(II) antitumour agents in vivo by reducing agents
such as glutathione.1b,7,14b,22 Thus, Pt(IV) based compounds can
be successfully used as cisplatin prodrugs. An example of such a
Pt(IV) complex is satraplatin, which can be orally administered
and becomes active aer reduction by ascorbate and gluta-
thione (GSH) in the malignant cells.8
Another approach to circumvent the shortcomings of
cisplatin is through targeted drug delivery systems.1b,9 A varietyThis journal is © The Royal Society of Chemistry 2015
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View Article Onlineof systems have been designed to release the drug only inside a
tumour cell, and to leave healthy cells untouched. Carbon
nanotubes,10 liposomes,1b,11 polymers1b,12 and nano-sized metal
phosphates1a or oxides13 are all under investigation as suitable
drug carriers. In addition to these systems, metal–organic
frameworks (MOFs) have recently come to the fore as drug
delivery systems, and may potentially be of use in cancer
therapy.14
MOFs are a comparatively new class of materials: they were
rst synthesised by Robson in 1989.15 They oﬀer great potential
in many applications, for example CO2 capture and hydrogen
storage,16 gas separation and purication,17 heterogeneous
catalysis,18 luminescence,19 MRI imaging20 and biomedicine.21
MOFs are porous materials with tunable surface areas and a
wide range of pore sizes.22 Methods exploiting their adsorption
capacities for drug storage and delivery are hence of increasing
interest.23 In this work, two biocompatible MOFs based on Zr
and 1,4-benzenedicarboxylate building blocks, UiO66 (Fig. 1)
and UiO66-NH2, were employed as cisplatin delivery devices.
In addition to the problems of non-specicity identied above,
anticancer therapy using cisplatin may lead to thrombosis:24 the
formation of blood clotting that may cause hypoxia and in
extreme cases tissue death, heart attacks and strokes. Entrapment
of nitric oxide (NO) – known for its anti-thrombosis, anti-
inammatory and anti-bacterial eﬀects14b,25 – in the cisplatin-
loaded MOFs, could mitigate this risk. Previous studies have
shown that NO can be stored and released on demand by the
MOFs HKUST-1, CPO-27-Mg and CPO-27-Ni.26 Nitric oxide itself
has also been reported to cause cancer cell death.27 Thus,
preparingMOFs loaded with both cisplatin and NO should permit
the production of dual-functionality systems without compro-
mising the anticancer eﬃcacy of the former.
In this work we examined whether we could successfully
encapsulate cisplatin in the UiO66 [Zr6O4(OH)4BDC]6 (BDC ¼ 1,4-
benzenedicarboxylate see Fig. 1) and UiO66-NH2 [Zr6O4(OH)4
(BDC-NH2)6] (BDC-NH2 ¼ 2-amino-1,4-benzenedicarboxylate)Fig. 1 The crystal structure of UiO66, based on CCSD deposition ﬁle
733458. Zr (green), O (red) and C (black) are represented by coloured
spheres.
This journal is © The Royal Society of Chemistry 2015MOFs, utilising their pores. Both UiO66 and UiO66-NH2 have
very high porosities, oﬀering octahedral (11 A˚ radius) and tetra-
hedral (8 A˚ radius) cages28,29 that could accommodate cisplatin,
which is ca. 5 A˚ in size.30 UiO66 and UiO66-NH2 have the same
basic structure, but the latter has a free amine group on the
organic linker. This means that while both systems can take
cisplatin up into their pores, UiO66-NH2 can also potentially form
covalent bonds with a guest through this amine group. For
the latter, we used a platinum prodrug with a carboxylic group,
cis,cis,trans-[PtIV(NH3)2Cl2(O2CCH2CH2CO2H)(OH)] (Fig. 2), and
UiO66-NH2. The idea was to conjugate the Pt(IV) prodrug to UiO66-
NH2 by covalent bonds similar to peptide bonds.
The major aim of our study was to determine which of these
approaches – encapsulation or conjugation – is more eﬃcient
for drug delivery. To ameliorate some of the common side
eﬀects of cisplatin therapy, bifunctional systems loaded with
nitric oxide were also prepared. We believe this study sheds
more light on using MOFs as drug delivery systems and
specically their potential supportive roles in cancer
treatments.Experimental section
All materials for MOF synthesis and cisplatin, cis-[Pt(NH3)2Cl2],
were obtained from Sigma Aldrich and used without further
purication. UiO66, UiO66-NH2 and cis,cis,trans-[Pt
IV(NH3)2-
(Cl)2(O2CCH2CH2CO2H)(OH)] were prepared according to liter-
ature procedures.31MOF synthesis
UiO66. A mixture of zirconium(IV) chloride (82 mg, 0.35
mmol) and 1,4-benzenedicarboxylic acid (58 mg, 0.35 mmol) in
dimethyl formamide (DMF; 5 mL) was acidied using HCl
(37 wt%, 805 mL, 9.7 mmol) and acetic acid (concentrated, 605
mL, 10.57 mmol). The solution was sealed inside a 23 mL Teon-
lined steel autoclave and heated at 220 C under autogenous
pressure for 24 hours. The UiO66 product was collected by
vacuum ltration, washed with DMF and dried in vacuum.
Yield: 117 mg, 84%.
UiO66-NH2. A mixture of zirconium(IV) chloride (82 mg, 0.35
mmol) and 2-amino-1,4-benzenedicarboxylic acid (63 mg,
0.35 mmol) in DMF (5 mL) was acidied using HCl (37 wt%, 805
mL 9.7 mmol) and acetic acid (concentrated, 605 mL, 10.57
mmol). The solution was sealed inside a 23 mL Teon-lined
steel autoclave and heated at 120 C under autogenous pres-
sure for 24 hours. The UiO66-NH2 product was collected byFig. 2 The structure of the cisplatin prodrug used in this work.
RSC Adv., 2015, 5, 83648–83656 | 83649
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View Article Onlinevacuum ltration, washed with DMF and dried in vacuum.
Yield: 130 mg, 90%.
Encapsulation method
For this method both MOFs (UiO66 and UiO66-NH2) were used.
The procedure was as follows: MOF powders (ca. 350 mg) were
dehydrated under dynamic vacuum overnight and then
immersed in a solution of cisplatin, cis-[Pt(NH3)2Cl2], (35 mL, at
80% of saturation solubility, 2 mgmL1, (6.66mM) in deionised
water). This corresponded to a theoretical loading of 29.8 mg of
cisplatin per 100 mg of dehydrated MOF. The encapsulation
continued for 48 hours under stirring at room temperature. The
samples were centrifuged and allowed to dry in air.
Prodrug synthesis
A prodrug of cisplatin, cis,cis,trans-[PtIV(NH3)2(Cl)2(O2CCH2-
CH2CO2H)(OH)] (see Fig. 2), was synthesised in the following
procedure. A suspension of cisplatin (0.4 g, 1.33 mmol) in H2O
(12 mL) at 60 C was oxidized with H2O2 (20 mL) added drop-
wise. The reaction was le for 4 h, and the resultant bright
yellow solution le to cool overnight. Yellow crystals (yield: 234
mg, 53%) were recovered by ltration and washed with ice cold
water. A more detailed procedure can be found in the liter-
ature.7a,32 The product (202 mg, 0.6 mol) was then reacted with
succinic anhydride (60 mg, 0.6 mol) at 70 C in a DMF (5 mL)
suspension for 24 h and then cooled to room temperature. DMF
was removed under vacuum and the residual suspension (1 mL)
was dissolved in acetone, and a pale yellow solid precipitated
with diethyl ether. Yield: 180 mg, 70%.
Incorporation of the prodrug into UiO66-NH2 (conjugation
method)
The prodrug (Fig. 2) was conjugated to UiO66-NH2 using the
EDC/NHS method in an aqueous solution. A detailed procedure
can be found in the literature.11b,33 In brief, 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide (EDC$HCl 0.038 g, 0.20
mmol) and N-hydroxysuccinimide (NHS 0.023 g, 0.20 mmol) were
dissolved in de-ionized water (15 mL) under stirring. Next, the
prodrug (0.70 g, 0.16 mmol) was added into the aqueous solution.
Aer the solution became clear, MOF UiO66-NH2 (0.140 g) was
added and the reactionmixture stirred at room temperature for 24
h. Finally, the solid product was recovered by vacuum ltration,
washed with water and le to dry in air. Elemental analysis of the
prodrug: calculated: [C] ¼ 11.06%, [H] ¼ 2.76%, [O] ¼ 6.45%,
found: [C] ¼ 10.75, [H] ¼ 2.67%, [O] ¼ 6.45%.
Nitric oxide loading
In order to activate (remove solvent from) the MOF powders
(0.015 g per glass vial), they were rst placed under vacuum (2.3
 103 bar) during which time ca. 30% of the mass was lost.
They were then heated to 120 C while still under dynamic
vacuum and held at this temperature overnight, leaving a fully
activated material. The samples were subsequently cooled to
room temperature and exposed to ca. 2 atm of dry NO (99.5%,
Air Liquide) for 45 min. The vials were next evacuated and83650 | RSC Adv., 2015, 5, 83648–83656exposed to dry argon, before being ame sealed. This cycle of
evacuation and argon ushing was repeated three times in
order to remove any residual physisorbed NO from the surfaces
of the MOF and glassware.
Drug release experiments
The drug-loaded UiO66-NH2 and UiO66 powders were formu-
lated into pellets using a hand press in order ensure repro-
ducibility in the drug release experiments. The pellets
contained 25 wt% of the drug-loaded MOF, with the remaining
75% being Teon. In each experiment, two pellets of 20 mg
each, were added to 10 mL of a pH 7.4 TRIS buﬀer (prepared
from 100mL 0.1 M TRIS, 84mL 0.1 MHCl, and 12mL deionised
H2O) at 37 C. Aliquots of 0.5 mL were removed aer the
following times: 15 min, 30 min, 1 h, 2 h, 3 h, 4 h, 5 h, 24 h.
Cisplatin release was quantied in terms of the amounts of Pt in
solution, using an Agilent MP4100 microwave plasma-atomic
emission spectrometer (MP-AES). Experiments were per-
formed in duplicate. All calculations for the extent of release are
related to the amount of active powder in a pellet.
Cell culture
The A549 lung cancer cell line (ATCC) was stimulated for 24 h
with the MOF formulations. The growth media used for cell
culture was Gibco RPMI 1640 supplemented with penicillin (100
mg mL1), streptomycin (100 mg mL1), L-glutamine (292 mg
mL1) (all Life Technologies) and 10% v/v heat-inactivated fetal
bovine serum (FBS; Gibco). This is henceforth referred to as
“complete RMPI”. Cells were incubated at 37 C (5% CO2) and
passaged in this medium until required for stimulation.
For the latter, 2% FBS in complete RPMI was used for cell
seeding. Cells were harvested with the TrypLE Express Enzyme
(1; Life Technologies) and seeded at a concentration of 40 000
cells per mL in a 96-well at bottomed plate, with 100 mL of cell
suspension added to each well. Suspensions of the MOF
formulations were prepared with a concentration of 1 mg/100
mL and aliquots of 10, 30 and 50 mL were used to stimulate
the cells. Complete RPMI was added to even up the volume in
wells to 150 mL over the plate. This corresponded to 100 mg, 300
mg and 500 mg of MOF per well respectively. A cisplatin solution
was prepared as a positive control, with a concentration of 1 mg
mL1 (3.33 mM). The aliquots used for cell stimulations were
the same as those for MOF powders: 10 mL (222 mM), 30 mL (666
mM) and 50 mL (1110 mM).
The Alamar Blue cell viability assay was used to evaluate cell
viability aer 24 h exposure to the MOFs. Resazurin solution (5
mM in RPMI) was added at 10% of the well volume (15 mL to 150
mL well volume), and incubated for 4 h. The uorescence of each
well was quantied using a SpectraMax Multi-Mode Microplate
reader (Molecular Devices) with excitation/emission wave-
lengths set at 555/585 nm. Aer 4 hours, a linear relationship
between uorescence intensity and cell number was observed.
The standard curve was constructed as follows: uorescence of
untreated cells corresponded to 100% viability and 0% cells
(RPMI media alone) to 0% viability, with additional calibration
points at 75%, 50% and 25%.This journal is © The Royal Society of Chemistry 2015
Fig. 3 SEM images of UiO66-NH2 (left) and UiO66 (right).
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View Article OnlineMaterial characterization and instrumentation
Powder X-ray diﬀraction (PXRD) patterns were collected on a
PANalytical Empyrean diﬀractometer using Cu Ka radiation.
Scanning electron microscopy-energy dispersive X-ray spec-
troscopy (SEM-EDX) was performed on a JEOL JSM-5600
instrument at a 20 keV excitation energy. Thermogravimetric
analysis (TGA) was conducted on a Discovery instrument (TA
Instruments) using approximately 2–3 mg of the sample, which
was heated at 10 C min1 to 800 C under a ow of N2 gas (25
mL min1). IR spectra were recorded over the region of 600–
4000 cm1 on a Shimadzu ATR spectrophotometer.
NO release measurements were performed using a Sievers
NOA 280i chemiluminescence analyzer. Calibration of the
instrument was performed by passing air through a zero lter
(Sievers < 1 ppb NO) and 91 ppm NO gas (AP, balance nitrogen).
The ow rate was set to 200 mLmin1 with a cell pressure of 8.5
Torr and an oxygen pressure of 6.1 psi. In order to trigger and
measure the NO release, dry nitrogen gas was humidied by
passing it over a solution of LiCl (sat.) to give 11% R.H.Results and discussion
Encapsulation of cisplatin in the pores of UiO66-NH2 and UiO66
Successful preparation of the MOFs was conrmed by X-ray
diﬀraction, with the patterns of the obtained materials being
identical to those reported in the literature. The particle size of
the MOFs was assessed by SEM to be around 500–600 nm
(Fig. 3). EDX quantication indicates that the cisplatin loading
is 4.7 wt% and 4.9 wt% for UiO66 and UiO66-NH2 respectively.
Pt : Zr ratios are shown in Table 1. The dose of cisplatin typically
used in anti-cancer therapy is 20 mg m2 per day for 5 days in
the case of testicular cancer and 75–100 mg m2 administered
every 4 weeks for ovarian cancer.34 An average male of 175 cm
weighing 80 kg has a body surface area of 1.99 m2 (according to
the Boyd formula35). Applying the same formula to an averageTable 1 Cisplatin loading calculated based on EDX analysis
MOF
Pt : Zr ratio
(mol)
Corresponding to
cisplatin loading wt%
UiO66-NH2-prodrug 1.00 : 1.76 30.7
UiO66-NH2 encapsulated 1.00 : 15.91 4.9
UiO66 encapsulated 1.00 : 17.38 4.7
This journal is © The Royal Society of Chemistry 2015female of 165 cm weighing 58 kg results in 1.63 m2. This would
mean that in order to use the MOFs loaded with cisplatin in
these therapies an amount of ca. 2.4–3.2 g would be necessary to
treat ovarian cancer, or approx. 0.8 g for testicular cancer, if
100% of the encapsulated cytotoxic material was released.Conjugation of the prodrug to the amine group of UiO66-NH2
The amide-coupling reaction allows for the direct incorporation
of a non-toxic Pt(IV) prodrug to the MOF using its amine group.
The Pt(IV) prodrug can be easily reduced in the oxygen-poor
environment typical of tumour cells to give cytotoxic Pt(II)
species. The UiO66-NH2 integrity was retained aer the prodrug
loading process: this is clear from the powder X-ray diﬀraction
data in Fig. 4, where the pattern is observed to be unchanged
post-incorporation. Attempts were made to reduce the Pt(IV)
prodrug with ascorbic acid7a and quantify the amount of
cisplatin released by 195Pt NMR, but the signal to noise ratio was
low and the results therefore inconclusive. However, EDX
analysis clearly demonstrates pro-drug conjugation (see Table
1). These data show that the ratio of Pt : Zr in the prodrug-
conjugated UiO66-NH2 is 1 : 1.76, which corresponds to 30.7
wt% loading (expressed w.r.t cisplatin) and indicates that
approximately every second amine group has successfully been
functionalised with the pro-drug. EDX mapping is shown in
Fig. 5. Pt and Zr are in the same areas of the image, indicating
the presence of a drug in the pores of the UiO66-NH2.
Infrared spectroscopy (Fig. 6) shows bands at around 1580
and 1730 cm1 corresponding to amide groups, proving a
peptide bond is formed between the Pt(IV) prodrug and the
amine group in UiO66-NH2. Small bands corresponding to
amine groups can also be seen, as not all available amine
groups on the MOF were involved in the conjugation. The band
at 1750 in the MOF, completely disappeared aer conjugation,
which can serve as a proof of a successful conjugation.
TGA was performed in order to assess the thermal stability of
the formulations. The data suggest that the MOF with a
conjugated cisplatin prodrug is not as thermally stable as the
unmodied UiO66-NH2, and starts decomposing at 300 C, (50
C lower than unmodied UiO66-NH2; Fig. 7).Fig. 4 Powder X-ray diﬀraction patterns of UiO66-NH2, before (blue)
and after (red) conjugation with a cisplatin prodrug. Plots are shifted
vertically for clarity.
RSC Adv., 2015, 5, 83648–83656 | 83651
Fig. 5 EDX mapping of UiO66-NH2 conjugated with the prodrug. Left: The SEM image of the studied area; centre and right: elemental mapping
of Pt and Zr by EDX. Red and green markings denote Pt and Zr, respectively.
Fig. 6 IR spectra of UiO66-NH2 before and after conjugation,
together with those of the prodrug and cisplatin. Spectra are vertically
shifted for clarity.
Fig. 7 Thermogravimetric analysis data for the materials explored in
this work.
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View Article OnlineDrug release. Cisplatin release data are given in Fig. 8. UiO66
releases 22.73 mg of cisplatin per mg of MOF in the rst 24
hours, approximately four times more than the amount
released from UiO66-NH2 (5.88 mg cisplatin per mg MOF).
However, the EDX analysis shows that the cisplatin loading is
similar in both MOFs (4.9 wt% in UiO66-NH2 and 4.7 wt% in
UiO66). The results possibly indicate a relatively strong inter-
action between cisplatin and the amine group in UiO66-NH2
MOF, preventing release of the former. As a result, aer 24 h
only 12.5% of loaded cisplatin in the active MOF powder is83652 | RSC Adv., 2015, 5, 83648–83656being released in the case of UiO66-NH2 while in UiO66 the
release amount is 48%.Cell viability studies
The lung cancer cell line A549 was stimulated with diﬀerent
MOF formulations and cell viability was examined aer 24 h
exposure using the Alamar Blue assay. This cell line was selected
for in vitro studies because cisplatin is commonly used to treat
lung cancer. The data are presented as mean  SEM (standard
error of the mean) from two independent experiments, with
each set of conditions run in triplicate in each experiment.
Statistical analysis was performed by Repeated Measures
ANOVA and Sidak's multiple comparisons test using GraphPad
Prism v6.05 soware. Diﬀerences between means were consid-
ered statistically signicant when P < 0.05 (*), P < 0.01 (**), P <
0.001 (***), or P < 0.0001 (****). “P” is the probability of
obtaining the observed eﬀect purely due to chance. P < 0.05 is
the conventional threshold for a statistically signicant result,
and indicates that there is only a 5% of chance that the
conclusion drawn is in fact false. Subsequent levels of signi-
cance commonly used in statistics are P < 0.01, P < 0.001, P <
0.0001, which denote 1%, 0.1% and 0.01% chance, respectively.
The lower the P value obtained, the higher the level of signi-
cance of the observed eﬀect and, consequently, the greater our
condence that it is true.
Fig. 9(a) shows the viability of cancer cells in response to UiO66
and UiO66-NH2 encapsulated with cisplatin at three diﬀerent
concentrations. We observed that cisplatin loaded UiO66 signi-
cantly decreased cell viability compared to UiO66 alone.
Conversely, the analogous UiO66-NH2 systems did not induce
signicant changes in cell viability. Thismay be due to the fact that
cisplatin bind to amine groups in the MOF, and is thus not
available for release and interaction with cells. These ndings
agree with the results from cisplatin release (discussion vide supra).
In Fig. 9(b), we compared the cytotoxic eﬃcacy of UiO66-NH2
with encapsulated cisplatin and UiO66-NH2 conjugated with the
cisplatin prodrug. It appears that the latter performed better in
inducing cell death, particularly at higher concentrations where
statistically signicant outcomes were observed. This is expec-
ted to be a result of the higher drug loading in the conjugated
system, as well as the binding between cisplatin and the amide
groups of UiO66-NH2. The conjugated UiO66-NH2 system shows
approximately the same cytotoxicity as the encapsulated UiO66This journal is © The Royal Society of Chemistry 2015
Fig. 8 Cisplatin release from UiO66 (violet) and UiO66-NH2 (red) pellets in TRIS buﬀer. The results of two independent experiments are shown
as mean  SEM.
Fig. 9 Cell viability after 24 h exposure to the MOF systems: (a) UiO66
and UiO66-NH2 with and without encapsulated cisplatin; (b) UiO66-
NH2 with encapsulated cisplatin and conjugated with the prodrug.
Results are from two separate experiments, each of them conducted
in triplicate, and are shown as mean  SEM.
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View Article Onlineat higher concentrations, but is less eﬀective at low concentra-
tions. This can be ascribed to the fact that the UiO66-
encapsulated cisplatin is freely able to exit the MOF, while for
the prodrug to be active hydrolysis of the amide linkage is
required. This makes the conjugated system require more time
to become active, but oﬀers promise for sustained release and
selectivity for cancerous cells only.
In all cases we observe a distinct dose-dependent eﬀect of the
drug-loaded MOFs on cell viability. It is clear that these systemsThis journal is © The Royal Society of Chemistry 2015are biologically functional, and thus have potential as drug
delivery systems.Nitric oxide adsorption
While UiO66 and UiO66-NH2 have high pore volumes, they do
not have any open metal sites with which to eﬀectively bind
nitric oxide, and in the two systems only the amine group in
UiO66-NH2 can perform this function. The amine group has in
this work been utilized for conjugation with the prodrug to
form a peptide bond. Nevertheless, cisplatin and the prodrug
themselves oﬀer open sites on their amine groups and Pt
centres.
NO-loading and NO release from the untreated MOFs and all
three drug-loaded materials were performed in triplicate. The
release proles are depicted in Fig. 10 and the absolute quan-
tities of NO involved are summarized in Table 2. The incorpo-
ration of cisplatin into the pores of the UiO66 material
signicantly increased the amount of NO loaded and released
from the system, since the cisplatin complex oﬀers two amine
groups and a metal site to which NO can bind.
The unmodied UiO66-NH2 shows more NO release than
UiO66 due to the presence of NH2 groups, which can form the
diazeniumdiolate group (NONOate)36 with NO. Again, the
encapsulation of cisplatin leads to a dramatic increase in NO
release capability. The amount of NO released is nearly 1500
times higher for UiO66 and ca. 3 times greater for UiO66-NH2
aer cisplatin encapsulation. We may thus assume that in
cisplatin loaded systems, nitric oxide can be coordinated to the
Pt and amine groups of cisplatin as well as to amine groups of
the organic linker in the case of UiO66-NH2. Note that the levels
of NO released are well above those required for anti-platelet
activation (anti-thrombosis) activity.37
In contrast, when UiO66-NH2 is conjugated with the
cisplatin prodrug there is almost no change in NO release
performance. This is thought to be because: (i) although the
introduction of the prodrug provides additional amine groups,
it also occupies the NH2 groups of the MOF, and (ii) the bulky
nature of the prodrug complex (see Fig. 1) may present steric
hindrance for the coordination of NO molecules to its amine
groups, reducing the ability of incoming NO to bind to them.RSC Adv., 2015, 5, 83648–83656 | 83653
Fig. 10 Total NO release from UiO66-NH2 (blue), UiO66-NH2
conjugated with the prodrug (green), and with cisplatin encapsulated
(red), and from UiO66 loaded with cisplatin (purple). Inset: NO release
from pure UiO66.
Table 2 Amounts of nitric oxide released from the MOFs, shown as
mean  SEM
MOF
Total NO
(mmoles per g of MOF)
UiO66 11.3  103  1.87
UiO66-NH2 9.27  3.95
UiO66-prodrug (conjugated) 7.69  0.43
UiO66-cisplatin (encapsulated) 16.5  4.25
UiO66-NH2-cisplatin (encapsulated) 22.7  5.53
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View Article OnlineConclusions
Using a solvothermal method, in this work we rst synthesized
the MOFs UiO66 and UiO66-NH2. We next loaded them with
cisplatin using two approaches – encapsulation of cisplatin to
both MOFs and conjugation of a cisplatin prodrug to UiO66-
NH2. The prodrug investigated, cis,cis,trans-[Pt
IV(NH3)2(-
Cl)2(O2CCH2CH2CO2H)(OH)] is expected to allow the selective
targeting of tumour cells because it is only reduced to an active
Pt(II) species under the highly reducing conditions typical of
such cells. The results obtained show that for UiO66-NH2
conjugation allows higher loading than encapsulation (30.7
wt% against 4.9 wt%), and that this translates into greater
cytotoxicity in an in vitro assay. Considering the encapsulated
systems, the amount of release of cisplatin from UiO66 is
signicantly higher than from UiO66-NH2, even though EDX
results suggest that the drug loading is similar in both systems.
This may be due to an interaction of cisplatin with amine
groups of the UiO66-NH2 MOF.83654 | RSC Adv., 2015, 5, 83648–83656In addition, the cisplatin loaded MOFs were successfully
loaded with NO, with the aim of preventing the thrombotic
eﬀects that can occur with cisplatin therapy. Nitric oxide release
is unaﬀected by the conjugation of the prodrug to UiO66-NH2.
However, MOFs loaded with cisplatin present much higher NO
release capacities than the pure materials, due to the open sites
available for NO binding on cisplatin.
To conclude, our results demonstrate a successful approach
for the synthesis of a bifunctional material containing Pt-based
anticancer agents and nitric oxide as both an antitumour and
antithrombotic agent.
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